

## Department of Health Care Finance 441 Fourth Street. NW 11<sup>th</sup> Floor Conference Room 1107 Main Washington DC, 20001



## PHARMACY & THERAPEUTICS COMMITTEE MEETING

December 3, 2015 Time: 2:30 PM – 5:30 PM

Call to Order Charlene Fairfax, RPh
 Minutes of Previous Meeting Charlene Fairfax, RPh

3) Comments from Interested Parties\* Charlene Fairfax, RPh

4) Clinical Drug Class Reviews Zakia Al-Amin, PharmD, BCACP RPh Ronald E. Kavanagh, BSPharm, PharmD, PhD, RPh

Acne Agents, Topical Beta-Blockers

Androgenic Agents Bone Resorption Suppression Agents

Angiotensin Modulator Combinations Calcium Channel Blockers

Angiotensin Modulators Growth Hormone Antianginal Agents (Ranexa) Hepatitis B Agents

Antibiotics, Inhaled Immunomodulators, Atopic Dermatitis
Antibiotics, Topical Immunomodulators, Topical

Anticoagulants Lipotropics, Others

Antihypertensives, Sympatholytics Lipotropics, Statins
Antihyperuricemics Pancreatic Enzymes

Antipsoriatics, Oral Platelet Aggregation Inhibitors

Antipsoriatics, Topical Progestins for Cachexia
Antiviral Agents, Oral (HSV & Influenza) Rosacea Agents, Topical (tentative)

Antiviral Agents, Topical

5) Executive Session (Committee Only)\*\* Charlene Fairfax, RPh

MMA Representatives

6) Final Recommendations of Preferred Drugs\*\*\* MMA Representatives

7) Announcement of Next Scheduled P&T Committee Meeting Charlene Fairfax, RPh

Thursday, March 3, 2015

8) Final Comments and Adjournment Charlene Fairfax, RPh

\*Individuals wishing to make oral presentations to the Committee will be limited to three (3) minutes only

<sup>\*\*</sup> Closed Session

<sup>\*\*\*</sup>Open Session